Get all your news in one place.
100's of premium titles.
One app.
Start reading
Inverse
Inverse
Benjamin Y. Fong, and ,The Conversation

The Future of Psychedelic Research Is In Limbo — Why the FDA’s Decision Changed Everything

— Stephen Simpson/Stockbyte/Getty Images

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. It is the first such decision issued on a psychedelic drug application.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.